阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效观察

目的 :评价在阿司匹林与噻氯匹啶合用基础上使用低分子肝素治疗不稳定型心绞痛疗效及安全性。方法 :不稳定型心绞痛 90例随机分成 3组 ,A组为常规治疗组 ,给予口服阿司匹林 ,每天 10 0 mg;B组为 A组加服噻氯匹啶。每天 2 5 0 m g;C组为在 B组治疗基础上 ,给予皮下注射低分子肝素 ,每次 0 .4 m l（410 0 U AXa WHO单位 ） ,除第 1天 12 h1次外 ,每天 1次。疗程均为 7d。各组均给予硝酸酯类、β受体阻滞剂、钙拮抗剂。结果 :A、B、C3组总有效率分别为 5 7%、6 3%、90 % ,C组总有效率与 A组比较有显著性差异 （P<0 .0 1）。随访 30 d,C组急性心脏事件发生率明显低于 A组 （P<0 .0 5 ） ,与 B组无显著性差异 （P>0 .0 5 ）。不良反应 ,3组间无显著性差异 （P>0 .0 5 ）。结论 :阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效确切 ,使用安全 ,且能减少急性心脏事件发生率

The therapeutic effect of co-administration of aspirin and ticlopidine and low molecular weight heparin on patients with unstable angina pectoris

AIM: To evaluate clinical effect of co-administration of aspirin, ticlopidine and low molecular weight heparin (LMWH) on unstable angina pectoris (UAP). METHODS: 90 UAP cases were randomly divided into the control aspirin group,the aspirin and ticlopidine group and the treated group (aspirin and ticlopidine combined with LMWH). The therapeutic course was one week. RESULTS: The effective rate was 90% in the treated group, 63% in the aspirin and ticlopidine group, and 57% in the control group after one weeks treatment. The effective rate was significantly higher in the treated group than in the control group ( P <0.01). The incidence of cardiac events was significantly lower in the treated group than in the control group ( P <0 05). CONCLUSION: Aspirin, ticlopidine and LMWH combined with normal treatment can effectively control angina pectoris and decrease incidence of cardiac event.